Advertisement

HindustanTimes Fri,19 Sep 2014

AstraZeneca rejects Pfizer’s sweetened £63-billion bid

Prasun Sonwalkar , Hindustan Times  London, May 02, 2014
First Published: 22:19 IST(2/5/2014) | Last Updated: 22:21 IST(2/5/2014)

British-Swedish pharma major AstraZeneca on Friday rejected the £63-billion (Rs 6,39,000 crore) takeover proposal of the US drugs giant Pfizer on the ground that it was inadequate and “substantially” undervalues the company.

Advertisement

If successful, it would have been the biggest takeover of a UK company by a foreign firm.

“Pfizer’s proposal would dramatically dilute AstraZeneca shareholders’ exposure to our unique pipeline and would create risks around its delivery. As such, the board has no hesitation in rejecting the proposal,” said Leif Johansson, chairman, AstraZeneca. “AstraZeneca continues to invest significantly in research, development and manufacturing in the UK, Sweden and the US. We are showing strong momentum as an independent company, in particular with our exciting, rapidly progressing pipeline, which the board believes will deliver significant value for shareholders”.

Pfizer had raised the price it was offering for AstraZeneca to 50 pounds a share, valuing the firm at £63 billion. Pfizer’s initial offer in January was worth £58.8 billion, or 46.61 pounds per share, which was rejected.

Earlier on Friday, Pfizer head Ian Read said “the industrial logic for a combination between Pfizer and AstraZeneca is compelling”.

Four scientific bodies had raised concerns about possible lab closures in the UK if the deal went ahead.


Advertisement
more from Business

Oracle's Ellison steps aside, co-CEOs Catz and Hurd take over

Larry Ellison, co-founder and leader of Oracle Corp for 37 years, stepped aside as chief executive officer on Thursday, to be replaced by co-CEOs Safra Catz and Mark Hurd, raising questions about a job-sharing arrangement that has had a fraught record elsewhere.
markets
Advertisement
Most Popular
Advertisement
Advertisement
Copyright © 2014 HT Media Limited. All Rights Reserved